.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
A recent ICMR study highlights the BPaL TB regimen India. This evaluation, published in the IJMR, shows that shorter treatment cycles for drug-resistant tuberculosis are cost-effective. Researchers at the NIRT compared six-month regimens against longer protocols. Their findings suggest these protocols enhance health outcomes and reduce costs.
The study focused on the BPaL regimen, including Bedaquiline, Pretomanid, and Linezolid. Additionally, it assessed the BPaLM regimen, which incorporates Moxifloxacin. The BPaL protocol is both effective and economical. The healthcare system saves Rs 379 per patient for every additional quality-adjusted life year gained. Consequently, this transition benefits both patients and providers.
Furthermore, the BPaLM regimen showed high cost-effectiveness. The analysis indicates an additional expenditure of just Rs 37 per patient per QALY. Both options offer a sustainable alternative to standard 9-to-11-month plans. Notably, these results underscore the importance of resource optimization.
Managing drug-resistant tuberculosis is traditionally very challenging. Long treatment durations often cause adverse effects and poor adherence. However, shorter all-oral regimens address these issues by simplifying the process. They reduce patient morbidity and enable a faster return to life. Moreover, these plans lower the overall burden on clinics. By aligning with national priorities, these regimens support TB elimination.
Q1: What is the primary advantage of the BPaL regimen?
The BPaL regimen reduces treatment duration from 18-20 months to just six months. Additionally, it is an all-oral treatment, which improves patient adherence.
Q2: How much does the health system save with the BPaL TB regimen India?
According to the ICMR study, the BPaL regimen saves Rs 379 per patient for each additional quality-adjusted life year gained.
Q3: Is the BPaLM regimen cost-effective?
Yes, the BPaLM regimen is highly cost-effective, costing only Rs 37 more per patient per additional QALY gained.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
ICMR study finds 6-month all-oral BPaL and BPaLM regimens for MDR-TB are highly cost-effective and improve patient outcomes compared to current long-term pl...
5 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
